Bcl-x L gene induces metastasis in the lung, lymph nodes and bone when breast cancer cells are inoculated in Nude Balb/c mice. In an attempt to identify the molecules required for diverse metastatic foci, we compared gene expression levels in tumor cells and metastatic variants with a cDNA GeneFilter containing 4000 known genes. The transcriptional regulators of α1-fetoprotein transcription factor, TBP-associated factor 172 (TAF-172), and the human zinc finger protein 5 (ZFP5) were down-regulated. The expression of TAF-172 was inversely proportional to Bcl-x L expression (ANOVA p<0.0001) and metastatic activity (ANOVA p<0.0001). A protein interaction program allowed us to functionally associate Bcl-x L and TAF through TBP proteins suggesting that Bcl-x L connects metabolic pathways with transcriptional machinery. The prediction included proteins involved in apoptosis, electron transfer, kinases, and transcription factors. These results indicate that the selection of diverse metastatic cells from the broad spectrum of tumor cell leads to the under-expression of certain transcriptional regulators that might act as adaptor molecules to different microenvironments, and indicate that the synergistic activity of several genes is needed for the selection process in several metastatic foci.
INTRODUCTION
Metastasis, the principal cause of treatment failure in cancer patients (1) , is a multi-step process characterized by multiple genetic alterations (2) (3) (4) . In breast carcinomas, the molecular and cellular mechanisms responsible for the growth of the metastatic phenotype are poorly understood. However, the phenotype has been described as resulting from interactions with the genetic background and from the relationship between the cells and their microenvironments (5) . The eventual outcome of metastasis is dependent on the "cross-talk" between the metastatic cells and the homeostatic factors that promote tumor growth (6) . Different hormone concentrations in individual organs, differentially expressed local factors, and paracrine growth factors may all influence the growth of malignant cells at particular sites (7) . Indeed, the microenvironment pressure determines the survival of those cells with mutations that render the gene active or inactive under specific conditions, thereby defining the cellular behavior at the metastatic foci (8, 9) .
The selective nature of the metastatic process, along with the rapid evolution and phenotypic diversification of clonal tumor growth, is the result of the inherent genetic and phenotypic instability of many clonal populations of tumor cells (10) . In addition to tumor heterogeneity and cell diversity, genetic changes driven by dynamic and stochastic evolutionary forces may occur, but such changes tend to mirror their somatic environment (11) . Thus, the ubiquity of metastatic cells might result from the genetic alterations that metastatic cells show in different somatic environments subject to varying constraints (12) .
Genetic instability has been linked to significant alterations in apoptosis control (13, 14) .
Moreover, apoptosis loss may be instrumental in the tolerance to the progressive accumulation of genomic damage, which facilitates the appearance of variants of increased malignant potential (15, 16) .
Several studies have reported a role for apoptosis resistance in metastasis, linking the development of the metastatic phenotype to the loss of apoptosis in cells (17, 18) . The antiapoptotic protein, Bcl-x L, , increases genetic instability in cells, leading to biological cell diversification and tumor heterogeneity. Moreover, different genetic changes in metastases from lung, bone and lymph node foci might allow the selection of the most adaptable organ-specific phenotype, which contributes to the observation that excellent responses to treatment do not necessarily result in cures (19) . Indeed, Bcl-x L mediates a phenotype in which redox pathways and glycolysis are coupled functions sheltering breast cancer metastatic cells from the primary tumor to the metastatic state (20) .
Since metastasis selection is a consequence of the evolution of the tumor history, many phenotypes induced by paracrine or autocrine signals, which differ in each metastasis and in each micro-environment, might be mediated by molecules acting as adaptors. The aim of this work is to provide insight into the phenotype induced by Bcl-x L in metastatic cells which results in a short dormancy period in several organs.
MDA-MB 435 cells, previously transfected with the anti-apoptotic Bcl-x L gene, induce metastasis in the lung, lymph node and bone when they are inoculated into the mammary fat pad (i.m.f.p)
in Nude Balb/c mice (21). The difference in gene expression levels in metastatic variants was analyzed by macro-arrays, thereby allowing several genes, which were either over-or underexpressed in relation to the tumor, to be identified. Specifically, we found a lower expression of transcriptional suppressors, whose under-expression might lead to the up-regulation of other genes. We also included 435 cells transfected with a pSFFV-Neo Bcl-2 construction, obtained as described (18) ; and 435 cells in which Bcl-x L anti-sense had been cloned in a ZeoSV2 construction (22).
MATERIAL AND METHODS

Human
cDNA arrays.-Total RNA was isolated from 1x10 6 cells of each variant using TrizolReagent (Life Technologies). RNA purity was measured using the spectrum, and RNA quality was examined in an agarose gel that was visualized with ethidium bromide.
The cDNA array GeneFilter GF211 Human Named Genes from Research Genetics (Huntsville, AL) contained: 3964 spots of 0.5 ng of cDNA, each corresponding to a known human gene; 192 positive controls, corresponding to spots of total genomic DNA; and 168 housekeeping genes whose signal was the same in all tissues when two different fluorescent dyes were used.
The array was hybridized with [ The background of each spot was subtracted from the raw intensity. Since each hybridization presents a different value, the process did not affect the general value, but it allowed us to eliminate those spots that had an intensity below 0.
In order to compare two images, Pathways software normalizes their hybridizations on the basis of the average total intensity of each filter. The formula used was: * data points / positive controls (Normalization = raw intensity /* raw intensity X 2000).
We calculated ratios dividing the normalized data point values of each metastasis by the normalized data point values of the tumor to detect genes that are differentially expressed in metastasis. The amounts of target and endogenous references were determined by drawing a standard curve for each sample. The standard was constructed from a pool of 5-fold serial dilutions of cDNA (375 ng, 75 ng, 15 ng, 3 ng, 0 ng). Each reaction was performed three times within one
Light
LightCycler run to confirm the intra-assay reproducibility. Inter-assay variation was assessed performing three different experiments.
In order to quantify gene expression, we used a mathematical model that determines the relative quantification of a target gene with that of the reference gene by using the crossing point (CP) and transcript efficiencies (E). propagating known interactions in one species to ortholog proteins in another species (i.e.
assuming protein-protein interologs) (28).
Using interactions from STRING (at a confidence level of 400) and the protein-protein interologs found by our algorithm, we built a protein-protein interaction network. Taking Data analysis.-The statistical analysis of the data was performed using SPSS for Windows.
Two-way analysis of variance was used to compare the mean expression levels. The nonparametric Kruskal-Wallis and Mann-Whitney U-test were also used for comparisons. In all the analyses, differences were considered significant when p< 0.05. Microsoft Excel was used to plot graphs. In order to detect the genes that were differentially expressed in the metastases, we only considered spots whose intensity was 10-fold higher than that of the background. In this way we eliminated spots that were more susceptible to error, because of their low intensity ( Fig. 2 A, B) .
RESULTS
Genes
All values were transformed to log 2 in order to calculate each metastasis/tumor ratio, having established that a significant ratio would be one that was higher than 1 (log 2 ratio ≥ 1) -overexpression -or lower than -1 (log 2 ratio ≤ -1) -under-expression.
Gene expression in lymph node metastases and in bone metastasis differed moderately from tumor gene expression ( Assuming that genes will be selected in all the metastatic variants in the broad spectrum of the metastatic process, we sought to identify changes that had occurred redundantly in lymph node, bone and lung. We found only eight genes whose expression had changed in all the metastases ( Table 1) . Two of these were over-expressed: monocarboxylate transporter (MCT3), which is a membrane protein; and collagen VIα 2 , which is an extracellular matrix protein. The six genes that were under-expressed were: a prostate membrane antigen and a receptor for the G protein, both of which were located in the cellular membrane; the LECT2 precursor, which is a neutrophil migration chemokine receptor; and three genes related to transcription: α1-fetoprotein transcription factor (hFTF), zinc finger protein 5 (ZFP5), and TBP-associated factor 172 (TAF-172).
We found 11 genes that were differentially expressed in the two lymph node metastases compared with that of the tumor (Figure 2 B ). These were: the eight common metastatic genes and three new over-expressed genes: integrin β1, the testis specific lactate dehydrogenase (LDHC4) and the apolipoprotein D.
Comparing these results with the information available in the literature and in public databases, we found that some genes had been previously described as aberrantly expressed in carcinomas, including breast cancer, which is consistent with our results (Table 1) .
Under-expression of transcriptional regulators.-We adopted two approaches for the independent confirmation of the array data: in silico analysis and quantitative real-time PCR.
Our results from the in silico analyses showed the under-expression of transcriptional regulators, which constitute an interesting phenotype for in-depth analysis. To assess the reliability of the array data further, experimental verification of ZFP5 and TAF-172 gene expression was carried out using real-time PCR.
As is shown in Figure 3 A, the TAF-172 expression level was lower in the metastatic variants than in the tumor cells (ANOVA, p<0. We then examined whether the expression of transcription suppressors was consistent with their metastatic activity (Fig 4 B) (Fig 4 A) . We found nine human-proteins On the other hand, TAF-172 interacts with a TBP subunit which connects TAF-172 and the beta-tubulin cofactor A, one of the members of the network (Table 2) . Consequently, TAF-172 gets related to Bcl-x L through this network by means of several proteins for which it has been experimentally proved their differential expression in metastasis. The pathway linking Bcl-x L and TAF-172 involves the root nodes of the network, tubulin-specific chaperone A (also named betatubulin cofactor A) and ATP synthase D chain, plus the connectors involved between them. In particular, proteins with functions such as "acetylation", "electron transfer", "protein transport"
and "extracellular matrix" appear to be involved in connecting ATP synthase D chain and the tubulin-specific chaperone A, while Bcl-x L is connect with the ATP synthase D chain through an apoptotic precursor.
In Table 3 Probably we should expect a more direct relationship between Bcl-x L and TAF-172, however there are no experimental evidences to prove an additional and closer intermediate. Perhaps it may be a clue the fact that the complex relationship we have found involves a large set of proteins from the redox system, whereas a close homolog of TAF-172 in Saccharomyces cerevisiae, Mot1, is a probable helicase also affected by oxidative stress.
In addition, the largest set of putative interactors of Bcl-x L included proteins involved in apoptosis: caspase-2, caspase-6 and caspase-7 precursors; Bcl-2/adenovirus E1B protein; baculoviral IAP repeat-containing protein 2 and 3. It is also noteworthy that proteins with functions such as "cell-division", "apoptosis", "transcription" and "DNA-repair" appear significantly involved in connecting Bcl-x L with REDOX proteins (peroxiredoxins 3 and 2).
We did not find any association between ZFP5 expression and the expression of anti-apoptotic proteins. ZFP5 is a nuclear DNA binding protein that functions as a transcriptional repressor of c-Myc oncogene (39) and thymidine kinase promoters (40). Several reports associate c-Myc over-expression and/or amplification with the prognosis of breast cancer (41). Moreover, a synergistic interaction between c-Myc and Bcl-2 oncogenes in the lymph node progression of human breast carcinomas has been described (42). Therefore, we believe that ZFP5 underexpression might be a phenotype that is selected early on in the metastatic process.
Since the expression levels of TAF-172 and ZFP5 genes in all the metastases were found to be lower than those in tumor cells, and the expression level was lower in metastatic variants than in breast cancer cells without metastatic ability, we conclude that these genes are directly associated with the metastatic process with putative metastatic suppressor activity. Note, the under-expression of TAF-172 in a panel of human breast cell lines has been reported previously (43). Neither gene type however is included in the group of genes associated with metastasis (44) or breast cancer prognosis (45).
We found that the majority of genes that are either over-expressed or under-expressed compared with tumor genes differed in each metastasis. These data imply that each metastasis has diverse taxonomies related to lung, lymph node and bone metastatic-specific growth, 
TABLE 1
Genes associated with the ubiquity of metastatic cells, their functional adscription, and references in which these genes are associated with breast cancer.
TABLE 2
Predicted graph of interactions that includes Bcl-x L and TAF-172 plus proteins identified by 2DE
and MALDI-TOF in a previous work with differential expression inmetastasis (España et al., 2005 ). 
